Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 13/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.42 |
| ▸ | MC4R | P32245 | 4/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | TEK | Q02763 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3741729 | 0.84 | CXCR3 (0.56) | GRIN2BGRIN1LCKKDRJAK3 | |
| SCHEMBL114749 | 0.81 | CXCR3 (0.43) | GRIN2BGRIN1MC4RLCKKDR | |
| SCHEMBL3739949 | 0.74 | CXCR3 (0.51) | GRIN2BKCNH2CXCR3 | |
| SCHEMBL17854893 | 0.74 | CXCR3 (0.61) | KCNH2CXCR3 | |
| SCHEMBL3731238 | 0.73 | CXCR3 (0.55) | GRIN2BGRIN1MC4RKCNH2CXCR3 | |
| SCHEMBL3730330 | 0.73 | CXCR3 (0.55) | GRIN2BGRIN1MC4RKCNH2CXCR3 | |
| SCHEMBL22965168 | 0.73 | CXCR3 (0.60) | GRIN2BGRIN1KCNH2CXCR3 | |
| SCHEMBL3726532 | 0.73 | CXCR3 (0.54) | GRIN2BGRIN1MC4RKCNH2CXCR3 | |
| SCHEMBL3728657 | 0.72 | CXCR3 (0.53) | KCNH2CYP2C9CXCR3 | |
| SCHEMBL3735603 | 0.71 | CXCR3 (0.59) | KCNH2CXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210380672-A1 | Treatment and Prevention of Cardiovascular Disease | Edifice Health, Inc. (US) | 2021-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380672-A1 | Treatment and Prevention of Cardiovascular Disease | SERPINA6, FABP3, CXCL8 | GRIN2B 4803/4885GRIN1 4805/4885MC4R 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.